Adeel Khan, Adeel Khan, MD, MPH, MS
![](https://education.binayfoundation.org/sites/default/files/styles/faculty_photo/public/faculty/2024-06/khan-adeel-1050x1500.jpg?itok=MWD6Za3t)
Dr. Adeel Khan is an Assistant Professor of Medicine and Public Health at UT Southwestern Medical Center. His primary appointment is in the Department of Internal Medicine as a member of its Division of Hematology/Oncology and his secondary appointment is in the Peter O'Donnell Jr School of Public Health. He specializes in myeloma, amyloidosis, and Waldenström macroglobulinemia and serves as the Director of Myeloma Epidemiology Research and Clinical Director of the Monoclonal Gammopathy Precursor Clinic.
Dr. Khan earned his medical degree with special distinction at the University of Michigan in Ann Arbor, Michigan, while also obtaining a master’s degree in public health from Harvard University. He performed a residency in internal medicine at the Cleveland Clinic and Lerner College of Medicine in Cleveland, Ohio. After serving as a hospitalist at Massachusetts General Hospital and an instructor at Harvard Medical School and concurrently obtaining a master's degree in epidemiology from Columbia University, he gained advanced training in hematology and oncology through a fellowship at Beth Israel Deaconess Medical Center and Harvard Medical School. He joined the UT Southwestern faculty in 2022.
Dr. Khan’s research interests include myeloma and other plasma cell disorders, as well as cancer epidemiology. He has delivered numerous presentations at large national conferences and published peer-reviewed articles related to his areas of expertise.
Financial relationships
-
Attribution:SelfType of financial relationship:Professional ServicesIneligible company:SanofiTopic:Honoraria/Food/BeverageDate added:06/19/2024Date updated:06/19/2024Relationship end date:06/08/2024
-
Attribution:SelfType of financial relationship:Professional ServicesIneligible company:JanssenTopic:Honoraria/Food/BeverageDate added:06/19/2024Date updated:06/19/2024Relationship end date:12/11/2022
-
Attribution:SelfType of financial relationship:Professional ServicesIneligible company:AstraZenecaTopic:Honoraria/Food/BeverageDate added:06/19/2024Date updated:06/19/2024Relationship end date:12/10/2022